Ocular permeation and inhibition of retinal inflammation: An examination of data and expert opinion on the clinical utility of nepafenac

Current Medical Research and Opinion

Volumn 22, Issue 2, 2006, Pages 397-404

  Lindstrom, Richard ^a   Kim, Terry ^b  

^a MINNESOTA EYE CONSULTANTS   (United States)

^b DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

Cataract surgery; Cystoid macular edema; Nepafenac; Nonsteroidal anti inflammatory drugs; NSAIDs

Indexed keywords

AMFENAC; BROMFENAC; CORTICOSTEROID; DICLOFENAC; DRUG VEHICLE; KETOROLAC TROMETAMOL; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRODRUG; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; BENZENEACETAMIDE DERIVATIVE; PHENYLACETIC ACID DERIVATIVE;

ANTERIOR EYE SEGMENT; ANTIINFLAMMATORY ACTIVITY; BLOOD RETINA BARRIER; CATARACT; CATARACT EXTRACTION; CLINICAL STUDY; CLINICAL TRIAL; CORNEA PERMEABILITY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG INHIBITION; DRUG STRUCTURE; DRUG UTILIZATION; EYE PAIN; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL LITERATURE; NONHUMAN; PHYSICAL EXAMINATION; PROTEIN SYNTHESIS; RETINA MACULA CYSTOID EDEMA; RETINITIS; REVIEW; RHEUMATOID ARTHRITIS; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZENEACETAMIDES; CATARACT EXTRACTION; CLINICAL TRIALS; HUMANS; MACULAR EDEMA, CYSTOID; PHENYLACETATES; RETINITIS; UNITED STATES;

EID: 33645745110     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1-11
2. Samiy N, Foster CS. The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Int Ophthalmol Clin 1996;36: 195-206
3. Lane SS, Modi SS, Holland EJ, et al. Nepafenac ophthalmic suspension 0.1% before and after surgery for postoperative anterior segment inflammation. Paper presented at: American Society of Cataract and Refractive Surgery, April 18, 2005, Washington, DC
4. Stewart WC, Stewart R, Maxwell WA, et al. Preoperative and postoperative clinical evaluation of nepafenac 0.1% ophthalmic suspension for postcataract inflammation. Paper presented at: American Society of Cataract and Refractive Surgery, April 18, 2005, Washington, DC
5. Donnenfeld ED, Holland EJ, Stewart R, et al. Topical xibrom 0.1% investigational NSAID to decrease inflammation after cataract surgery. Paper presented at: American Society of Cataract and Refractive Surgery, April 18, 2005, Washington, DC
6. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol 1999;127: 253-9
7. Yee RW, Ketorolac Radial Keratotomy Study Group. Analgesic efficacy and safety of nonpreserved ketorolac ophthalmic solution following radial keratotomy. Am J Ophthalmol 1998;125:472-80
8. Eiferman RA, Hoffman RS, Sher NA. Topical diclofenac reduced pain following photorefractive keratectomy. Arch Ophthalmol 1993;111:1022
9. Szerenyi K, Sorken K, Garbus JJ, et al. Decrease in normal human corneal sensitivity with topical diclofenac sodium. Am J Ophthalmol 1994;118:312-5
10. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin 2004;20:2015-9
11. Jampol LM. Pharmacologic therapy of aphakic cystoid macular edema: a review. Ophthalmology 1982;89:891-7
12. Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000;24:357-70
13. Ke TL, Graff G, Spellman JM, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000;24:371-84
14. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003;27;281-91
15. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimized cataract surgery patient care. Curr Med Res Opin 2005;21:1131-7
16. Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol 2000;44:58-67
17. Bringmann A, Reichenbach A, Wiedemann P. Pathomechanisms of cystoid macular edema. Ophthalmic Res 2004;36;241-9
18. McColgin AZ, Raizman MB. Efficacy of topical Voltaren in reducing the incidence of post operative cystoid macular edema. Invest Ophthmol Vis Sci 1999;40:S289
19. Sivaprasad S, Bunce C, Patel N. Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database Syst Rev 2005;1:CD004239
20. Solomon LD. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema [Flurbiprofen-CME Study Group]. J Cataract Refract Surg 1995;21:73-81
21. Ginsburg AP, Cheetham JK, DeGryse RE, et al. Effects of flurbiprofen and indomethacin on acute cystoid macular edema after cataract surgery: functional vision and contrast sensitivity. J Cataract Refract Surg 1995;21:82-92
22. Miyake K, Sakamura S, Miura H. Long-term follow-up study on prevention of aphakic cystoid macular oedema by topical indomethacin. Brit J Ophthalmol 1980;64:324-8
23. Flach AJ, Stegman RC, Graham J, et al. Prophylaxis of aphakic cystoid macular edema without corticosteroids: a paired-comparison, placebo-controlled double-masked study. Ophthalmology 1990;97:1253-8
24. Rome LH, Lands WE. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 1975;72:4863-5
25. Walsh DA, Sancilio LF, Reese DL. Aroyl- and arylisoquinoline-acetic acids as antiinflammatory agents. J Med Chem 1978;21:582-5
26. Walsh DA, Moran HW, Shamblee DA, et al. Anti-inflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues. J Med Chem 1984;27:1379-88
27. Walsh DA, Moran HW, Shamblee DA, et al. Anti-inflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chloro-benzoyl) benzeneacetic acid. J Med Chem 1990;33:2296-304
28. Kulkarni P S. The role of endogenous eicosanoids in rabbit-intraocular inflammation. J Ocul Pharmacol 1991;7:227-41
29. Srinivasan BD, Kulkarni PS. Inhibitors of the arachidonic acid cascade in the management of ocular inflammation. Prog Clin Biol Res 1989;312:229-49
30. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-7